© 2021 MJH Life Sciences and Oncology Nursing News. All rights reserved.
© 2021 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
August 10, 2021
“We want to make sure we can provide the right treatment for the right patient at the right time,” says Olufunmilayo I. Olopade, MD, FACP, OON.
With a newfound abundance of available oral cancer therapies, it has become necessary for oncology nurses to ensure that their patients are adhering to treatment.
August 05, 2021
CDK4/6 inhibitors have demonstrated promise in treating patients with estrogen receptor (ER)–positive, HER2-negative breast cancer in both a neoadjuvant and adjuvant setting.
July 27, 2021
The FDA has approved the first immunotherapy, pembrolizumab (Keytruda), to treat patients with high-risk early-stage triple-negative breast cancer.
July 23, 2021
Study results have posited plinabulin as a potentially effective preventative and active therapy due to its unique mechanism of action.
June 27, 2021
Regardless of clinical risk, the survival prognosis of patients with early-stage breast cancer is high amongst those who have ultralow risk disease indicated by a 70-gene signature.
June 08, 2021
Sacituzumab govitecan, an antibody drug conjugate, maintained survival and response benefits over chemotherapy regimens.
June 04, 2021
Patients with BRCA1/2-mutant, early HER2-negative breast cancer at a high risk of recurrence saw a clinically meaningful benefit 1 year after standard of care when treated with olaparib.
May 28, 2021
Public health efforts must address new methods of cancer screening, an expert says.
May 10, 2021
A 9-week trastuzumab regimen may be favorable for patients with HER2-positive early breast cancer who have low and intermediate risk factors.